New menopause drug to target hot flashes without hormones gets FDA approval

The US Food and Drug Administration has approved another once-a-day pill that works without hormones to treat moderate to severe hot flashes in menopausal women, drugmaker Bayer said Friday.
Healio

Blenrep rebounds after FDA setback with approval for relapsed, refractory multiple myeloma

The FDA approved belantamab mafodotin-blmf in combination with bortezomib and dexamethasone for the treatment of certain ...

Syndax Pharmaceuticals, Inc. (SNDX) Discusses FDA Approval of Revuforj for Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia Transcript

Syndax Pharmaceuticals, Inc. ( NASDAQ: SNDX) Discusses FDA Approval of Revuforj for Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia October 24, 2025 2:30 PM EDT ...
TipRanks on MSN

FDA approves Syndax’s revumenib for relapsed or refractory AML

The Food and Drug Administration approved revumenib, or Revuforj, from Syndax (SNDX) Pharmaceuticals, a menin inhibitor, for relapsed or ...